In addition, compared with KRAS‐wild‐type tumors, other KRAS‐mutated tumors were also associated with a higher 5‐year colorectal cancer‐specific mortality (with univariable HR, 1.63; 95% CI, 1.27–2.09; p = 0.0001; and multivariable HR, 1.57; 95% CI, 1.22–2.02; p = 0.0004). The gene discussed is KRAS; the disease is colorectal cancer.